TrialPath
Recruiting

Neurofeedback Rehabilitation With FES and VR for PD

NCT06690931 · g.tec medical engineering GmbH
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Parkinson's Disease Rehabilitation Using Neurofeedback With Functional Electrical Stimulation and Virtual Reality Feedback for Lower Extremities
About this study
recoveriX PRO system is a Brain-Computer Interface (BCI) device that combines Motor Imagination (MI), with Functional Electrical Stimulation (FES) and Virtual Reality (VR) as feedback devices. The user wears an electroencephalography (EEG) cap that registers the neural activity during the mental practice. This system allows the user to control the feedback devices (FES +VR) with the MI. The goal of this clinical trial is to know the safety and clinical effectiveness of recoveriX-based treatment for improving motor functions in Parkinson's Disease patients. Researchers will compare the functional results obtained by recoveriX system, to the standard treatment based in FES + VR + MI without monitoring the EEG activity. The questions to answer are: 1. Will Parkinson's patients who undergo recoveriX therapy significantly improve their motor functions? 2. Is the functional improvement achieved with the BCI treatment superior to the standard MI+FES+VR treatment? 3. Is the recoveriX-based therapy as safe as the standard treatment? Participants will have to perform a complete assessment to evaluate their functionality before and after the intervention (motor skills, walking ability, fatigue, impact of the disease in daily living activities). Patients in the BCI group will receive 6 sessions per week during 4 weeks of BCI training with FES and VR feedback (24 sessions in total). Patients in the control group receive 6 sessions of FES + VR therapy per week for 4 weeks (24 sessions in total). Patients in the control group will receive the same instructions as the experimental but will not wear the EEG cap.
Eligibility criteria
Inclusion Criteria: * Diagnosis of PD * HY stage between 1 to 3 * Age between 40 - 80 years old * Ability to walk independently * Stable medication usage * Stable neurological condition * Able to sign the informed consent. * Able to follow the study protocol. Exclusion Criteria: * Other neurological diseases * Severe depression * Uncontrolled diabetes * Concomitant severe neurologic, cardiopulmonary, or orthopedic disorders * Debilitating conditions or vision impairment that would impede full participation in the study. * Unpredictable motor fluctuations * Pregnant * Active or passive implanted medical devices such as pacemakers which do not allow the use of FES. * Implanted metallic fragments in the upper and lower extremities which can limit the use of FES. * Under the influence of anesthesia or similar medication. * With fractures or lesions in the upper and lower extremities. * Inadequate control of a BCI system.
Study design
Enrollment target: 30 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2024-12-09
Estimated completion: 2027-08
Last updated: 2025-05-09
Interventions
Device: Brain-Computer Interface with FES and VRDevice: Motor imagery with Functional Electrical Stimulation and Virtual Reality feedback
Primary outcomes
  • Movement Disorders Society - Unified Parkinson's Disease Rating Scale Section III (All patients will be evaluated two pre-assessments before (at week 0 and week 1) and two post-assessments (at week 5, and week 7) after the intervention.)
Sponsor
g.tec medical engineering GmbH · industry
Contacts & investigators
ContactRupert Ortner, PhD · contact · ortner@gtec.at · +43725122240
ContactMarc Sebastián-Romagosa, PhD · contact · sebastian@gtec.at · +34936764579
All locations (1)
g.tec medical engineering GmbHRecruiting
Schiedlberg, Upper Austria, Austria
Neurofeedback Rehabilitation With FES and VR for PD · TrialPath